MSD Partners’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

MSD Partners’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,113	Closed	-$26.5K	–	71
2023 Q3	$26.5K	Buy	+5,113	New	+$36.9K	﹤0.01%	58
2023 Q2	–	Sell	-5,113	Closed	-$60.3K	–	75
2023 Q1	$60.3K	Hold	5,113	–	–	0.01%	55
2022 Q4	$73.6K	Sell	5,113 -7,843	-61%	-$262K	0.01%	60
2022 Q3	$649K	Hold	12,956	–	–	0.05%	53
2022 Q2	$1.1M	Hold	12,956	–	–	0.07%	53
2022 Q1	$1.96M	Sell	12,956 -25,913	-67%	-$5.98M	0.11%	49
2021 Q4	$11.6M	Buy	38,869 +25,913	+200%	+$9.94M	0.13%	49
2021 Q3	$5.05M	Buy	12,956 +5,113	+65%	+$2.18M	0.15%	37
2021 Q2	$3.31M	Sell	7,843 -5,113	-39%	-$2.21M	0.09%	57
2021 Q1	$6.28M	Buy	+12,956	New	+$6.6M	0.24%	39

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MSD Partners's FNCH Position: Q4 2023 in Review

MSD Partners sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q4 2023, closing a stake of 5,113 shares — an estimated $26.5K sold.

MSD Partners first reported a position in FNCH in Q1 2021 and held it in 10 quarters. The position peaked at $11.6M in Q4 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q4 2023.

MSD Partners reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
MSD Partners sold 5,113 Finch Therapeutics Group, Inc. Common Stock shares in Q4 2023, an estimated $26.5K.
MSD Partners first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
MSD Partners's Finch Therapeutics Group, Inc. Common Stock position peaked at $11.6M in Q4 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q4 2023.

Based on MSD Partners's 13F filing for Q4 2023, filed 14 Feb 2024.